ZURICH (Reuters) – Novartis will seek regulatory approval this year for a new kind of anti-inflammatory heart drug, though some experts fear fatal infection risks and a high price may overshadow the medicine’s limited benefits.
Keenly awaited clinical trial results released on...
https://goo.gl/X44WuK
Sunday, 27 August 2017
Novartis hopeful for novel heart drug, despite 'modest' benefit
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment